PL1942108T3 - Związek zawierający grupę zasadową i jego zastosowanie - Google Patents

Związek zawierający grupę zasadową i jego zastosowanie

Info

Publication number
PL1942108T3
PL1942108T3 PL06822530T PL06822530T PL1942108T3 PL 1942108 T3 PL1942108 T3 PL 1942108T3 PL 06822530 T PL06822530 T PL 06822530T PL 06822530 T PL06822530 T PL 06822530T PL 1942108 T3 PL1942108 T3 PL 1942108T3
Authority
PL
Poland
Prior art keywords
compound containing
basic group
containing basic
group
compound
Prior art date
Application number
PL06822530T
Other languages
English (en)
Inventor
Masaya Kokubo
Motoyuki Tanaka
Hiroshi Ochiai
Yoshikazu Takaoka
Shiro Shibayama
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of PL1942108T3 publication Critical patent/PL1942108T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/695Silicon compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL06822530T 2005-10-28 2006-10-27 Związek zawierający grupę zasadową i jego zastosowanie PL1942108T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005313796 2005-10-28
PCT/JP2006/321569 WO2007049771A1 (ja) 2005-10-28 2006-10-27 塩基性基を含有する化合物およびその用途
EP06822530.9A EP1942108B1 (en) 2005-10-28 2006-10-27 Compound containing basic group and use thereof

Publications (1)

Publication Number Publication Date
PL1942108T3 true PL1942108T3 (pl) 2014-03-31

Family

ID=37967879

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06822530T PL1942108T3 (pl) 2005-10-28 2006-10-27 Związek zawierający grupę zasadową i jego zastosowanie

Country Status (8)

Country Link
US (3) US8318931B2 (pl)
EP (2) EP1942108B1 (pl)
JP (2) JP5251127B2 (pl)
DK (1) DK1942108T3 (pl)
ES (1) ES2427989T3 (pl)
PL (1) PL1942108T3 (pl)
PT (1) PT1942108E (pl)
WO (1) WO2007049771A1 (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008016006A1 (fr) * 2006-07-31 2008-02-07 Ono Pharmaceutical Co., Ltd. Composé auquel un groupe cyclique est lié par une liaison spiro et son utilisation
EP2161256A1 (en) * 2008-09-08 2010-03-10 Atomic Energy Council - Institute of Nuclear Energy Research Compound containing carboxylate ester and N2S2 ligand bi-functional groups and manufacturing method thereof
WO2010077613A1 (en) * 2008-12-09 2010-07-08 Gilead Sciences, Inc. Modulators of toll-like receptors
US8476290B2 (en) 2009-06-16 2013-07-02 Ono Pharmaceutical Co., Ltd. Compound having spiro-bonded cyclic group and use thereof
HRP20161774T1 (hr) * 2012-06-13 2017-02-24 F. Hoffmann - La Roche Ag Novi diazaspirocikloalkan i azaspirocikloalkan
BR112015004111A2 (pt) 2012-09-25 2017-07-04 Hoffmann La Roche novos derivados bicíclicos
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
US10144747B2 (en) 2013-07-09 2018-12-04 Lehigh University Reagents and methods for fluorinating a substrate
KR20160087900A (ko) 2013-11-26 2016-07-22 에프. 호프만-라 로슈 아게 신규한 옥타하이드로-사이클로부타[1,2-c;3,4-c'']다이피롤-2-일
KR20160128428A (ko) 2014-03-26 2016-11-07 에프. 호프만-라 로슈 아게 오토탁신(atx) 및 리소포스파티드산(lpa) 생성 억제제로서의 축합형 [1,4]다이아제핀 화합물
SI3122750T1 (sl) 2014-03-26 2019-12-31 F. Hoffmann-La Roche Ag Biciklične spojine kot zaviralci proizvodnje avtotaksina (ATX) in lizofosfatidne kisline (LPA)
CN105705427B (zh) 2014-04-09 2017-06-06 株式会社可乐丽 液体包装容器
EP4140485A1 (en) 2014-07-11 2023-03-01 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
EA201790369A1 (ru) 2014-09-16 2017-10-31 Джилид Сайэнс, Инк. Твердые формы модулятора толл-подобного рецептора
JP6373490B2 (ja) * 2014-09-16 2018-08-15 ギリアード サイエンシーズ, インコーポレイテッド Toll様受容体モジュレーターを調製する方法
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
JP6886967B2 (ja) 2015-09-04 2021-06-16 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft フェノキシメチル誘導体
CN107635995B (zh) 2015-09-24 2022-08-19 豪夫迈·罗氏有限公司 作为atx抑制剂的二环化合物
AU2016328365B2 (en) 2015-09-24 2020-04-23 F. Hoffmann-La Roche Ag New bicyclic compounds as dual ATX/CA inhibitors
RU2018112230A (ru) 2015-09-24 2019-10-30 Ф. Хоффманн-Ля Рош Аг Бициклические соединения в качестве ингибиторов atx
JP6877413B2 (ja) 2015-09-24 2021-05-26 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 二重atx/ca阻害剤としての新規な二環式化合物
WO2018167113A1 (en) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag New bicyclic compounds as atx inhibitors
EP3596059B1 (en) 2017-03-16 2024-04-24 F. Hoffmann-La Roche AG Heterocyclic compounds useful as dual atx/ca inhibitors
CN109761979B (zh) * 2019-03-19 2020-04-17 中国医学科学院医药生物技术研究所 一种含3-三氟甲基-苯基取代基的二氮杂螺环类衍生物及其制备方法和应用
EP3769761A1 (en) * 2019-07-26 2021-01-27 Charité - Universitätsmedizin Berlin Cxcr4 antagonists for treatment of cardiovascular conditions

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE555319A (pl) 1956-03-21 1900-01-01
US3095355A (en) 1961-10-12 1963-06-25 Revlon Aerosol composition
GB8334626D0 (en) 1983-12-30 1984-02-08 Exxon Research Engineering Co Zeolite coated substrates
WO1997044329A1 (en) 1996-05-20 1997-11-27 Teijin Limited Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists
AU5803398A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
WO1999004794A1 (en) 1997-07-25 1999-02-04 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
GB9716657D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
IL125658A0 (en) 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
AR013669A1 (es) 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos
WO1999032100A2 (en) 1997-12-19 1999-07-01 Takeda Chemical Industries, Ltd. Pharmaceutical composition for antagonizing ccr5 comprising anilide derivative
DE19801265C1 (de) 1998-01-15 1999-08-12 Deutsches Krebsforsch Inhibierung von CD95-unabhängiger Apoptose bei AIDS
AU2654399A (en) 1998-02-02 1999-08-16 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
GB9803226D0 (en) 1998-02-17 1998-04-08 Zeneca Ltd Chemical compounds
EP1076557A1 (en) 1998-04-27 2001-02-21 Smithkline Beecham Corporation Ccr-3 receptor antagonists
CA2329821A1 (en) 1998-04-27 1999-11-04 Dashyant Dhanak Ccr-3 receptor antagonists
WO2000004003A1 (en) 1998-07-14 2000-01-27 Smithkline Beecham Corporation Ccr-3 receptor antagonists
JP2002521441A (ja) 1998-07-28 2002-07-16 スミスクライン・ビーチャム・コーポレイション Ccr5モジュレーターとしてのプロペンアミド
JP2002521436A (ja) 1998-07-28 2002-07-16 スミスクライン・ビーチャム・コーポレイション 置換アニリド化合物および方法
EP1102535A4 (en) 1998-07-28 2004-09-29 Smithkline Beecham Corp COMPOUNDS AND METHODS
WO2000010965A2 (en) 1998-08-20 2000-03-02 Takeda Chemical Industries, Ltd. Quaternary ammonium salts and their use as anti-hiv agents
WO2000021916A1 (fr) 1998-10-15 2000-04-20 Takeda Chemical Industries, Ltd. Procede de preparation de derives d'amine
WO2000027835A1 (en) 1998-11-09 2000-05-18 Smithkline Beecham Corporation Ccr-3 receptor antagonists
WO2000027800A1 (en) 1998-11-09 2000-05-18 Smithkline Beecham Corporation Ccr-3 receptor antagonists
WO2000027843A1 (en) 1998-11-09 2000-05-18 Smithkline Beecham Corporation Ccr-3 receptor antagonists
ATE280157T1 (de) 1998-11-17 2004-11-15 Hoffmann La Roche 4-aroyl-piperidin-ccr-3 rezeptor antagonisten iii
WO2000031033A1 (en) 1998-11-20 2000-06-02 F. Hoffmann-La Roche Ag Piperidine ccr-3 receptor antagonists
CN1158256C (zh) 1998-11-20 2004-07-21 霍夫曼-拉罗奇有限公司 吡咯烷衍生物-ccr-3受体拮抗剂
CA2319435A1 (en) 1998-12-04 2000-06-15 Toray Industries, Inc. Triazolo derivatives and chemokine inhibitors containing the same as effective component
WO2000035454A1 (en) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
EP1140834A1 (en) 1998-12-18 2001-10-10 Du Pont Pharmaceuticals Company Heterocyclic piperidines as modulators of chemokine receptor activity
CA2350730A1 (en) 1998-12-18 2000-06-22 George V. Delucca N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
WO2000035876A1 (en) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity
US6444686B1 (en) 1998-12-18 2002-09-03 Brsitol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
DE69926919D1 (de) 1998-12-18 2005-09-29 Bristol Myers Squibb Pharma Co N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
EP1156807A4 (en) 1998-12-18 2002-04-03 Du Pont Pharm Co N-UREIDOALKYL-PIPERIDINES FOR USE AS MODULATORS OF THE ACTIVITY OF CHIMIOKIN RECEPTORS
WO2000037455A1 (en) 1998-12-21 2000-06-29 Takeda Chemical Industries, Ltd. Benzothiepin-anilide derivatives, their production and their use for antagonizing ccr-5
PE20001420A1 (es) 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
EP1013276A1 (en) 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
US7217714B1 (en) 1998-12-23 2007-05-15 Agouron Pharmaceuticals, Inc. CCR5 modulators
EP1140072B1 (en) 1998-12-30 2004-04-14 Smithkline Beecham Corporation Compounds and methods
AP2001002228A0 (en) 1999-01-13 2001-09-30 Millenium Pharmaceuticals Inc Functionalized heterocycles as chemokine receptor modulators.
WO2000041685A1 (en) 1999-01-19 2000-07-20 Smithkline Beecham Corporation Ccr-3 receptor antagonists
JP2002535256A (ja) 1999-01-25 2002-10-22 スミスクライン・ビーチャム・コーポレイション 化合物および方法
GB9902459D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902461D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902453D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902452D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902455D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
JP2000309598A (ja) 1999-02-25 2000-11-07 Takeda Chem Ind Ltd 多剤結合型新規化合物、その製造法および用途
WO2000051608A1 (en) 1999-03-02 2000-09-08 Merck & Co., Inc. 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity
WO2000051609A1 (en) 1999-03-02 2000-09-08 Merck & Co., Inc. 3-alkyl substituted pyrrolidine modulators of chemokine receptor activity
WO2000051610A1 (en) 1999-03-02 2000-09-08 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
WO2000051607A1 (en) 1999-03-02 2000-09-08 Merck & Co., Inc. 3-cyclopropyl and 3-cyclobutyl pyrrolidine modulators of chemokine receptor activity
WO2000053172A1 (en) 1999-03-08 2000-09-14 Smithkline Beecham Corporation Ccr-3 receptor antagonists
EP1156801B1 (en) 1999-03-10 2004-07-07 Smithkline Beecham Corporation SUBSTITUTED BENZO(1,2-b:5,4-b')DIPYRAN-4-AMINES AS CCR5 MODULATORS
AU2942000A (en) 1999-03-11 2000-09-28 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivatives
AP1654A (en) 1999-03-24 2006-09-01 Anormed Inc Chemokine receptor binding heterocyclic compounds.
KR20010108394A (ko) 1999-03-26 2001-12-07 다비드 에 질레스 신규 화합물
US6248755B1 (en) 1999-04-06 2001-06-19 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
US6498161B1 (en) 1999-04-06 2002-12-24 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
US6265434B1 (en) 1999-04-06 2001-07-24 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
US6399619B1 (en) 1999-04-06 2002-06-04 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
US6358697B2 (en) 1999-04-21 2002-03-19 Children's Hospital Medical Center Intracellular pharmaceutical targeting
CA2371618A1 (en) 1999-04-28 2000-11-09 Yuji Ishihara Cyclic amide compounds, their production and use
EP1189609A4 (en) 1999-05-03 2002-10-30 Smithkline Beecham Corp CXCR-4 RECEPTOR ANTAGONISTS AND THROMBOPOIETIN MIMETIKA
EP1175402B1 (en) 1999-05-04 2005-07-20 Schering Corporation Piperidine derivatives useful as ccr5 antagonists
EP1175224B1 (en) 1999-05-04 2005-02-23 Schering Corporation Pegylated interferon alfa-ccr5 antagonist combination hiv therapy
TR200103214T2 (tr) 1999-05-04 2002-03-21 Schering Corporation CCR5 antagonistleri olarak yararlì piperazin trevleri.
WO2000068203A1 (en) 1999-05-07 2000-11-16 Takeda Chemical Industries, Ltd. Cyclic compounds and uses thereof
AU4796700A (en) 1999-05-13 2000-12-05 Dupont Pharmaceuticals Research Laboratories, Inc. Ureido-substituted cyclic amine derivatives and their use as drug
DE60023878T2 (de) 1999-05-18 2006-07-20 Teijin Ltd. Heilmittel und vorbeugung für mit chemokinen verbundenen erkrankungen
MXPA01012165A (es) 1999-05-27 2003-06-30 Celltek Biotechnologies Inc Antagonistas ccr3 del receptor de quimiocina.
US6165261A (en) 1999-06-10 2000-12-26 Ergon, Inc. Water-resistant gypsum composition
WO2001009088A1 (en) 1999-07-28 2001-02-08 Kirin Beer Kabushiki Kaisha Urea derivatives as inhibitors of ccr-3 receptor
WO2001028987A1 (en) 1999-10-15 2001-04-26 Du Pont Pharmaceuticals Company Benzylcycloalkyl amines as modulators of chemokine receptor activity
AU2002213467A1 (en) 2000-10-11 2002-04-22 Chemocentryx, Inc. Modulation of ccr4 function
AU2002213466A1 (en) 2000-10-11 2002-04-22 Chemocentryx, Inc. Compounds and methods for modulating ccr4 function
WO2002094261A1 (fr) 2001-05-24 2002-11-28 Kureha Chemical Industry Company, Limited Medicaments antagonistes de cxcr4 comprenant un compose contenant de l'azote
US6693134B2 (en) 2001-05-29 2004-02-17 Chemokine Therapeutics Corporation Bicyclic aromatic chemokine receptor ligands
JP2002371042A (ja) 2001-06-12 2002-12-26 Takeda Chem Ind Ltd ジアミン化合物、その製造法および用途
JPWO2003029218A1 (ja) 2001-09-28 2005-01-13 呉羽化学工業株式会社 新規含窒素化合物及びその用途
WO2003079020A2 (en) 2002-03-20 2003-09-25 Dana-Farber Cancer Institute Inc. Methods and compositions for the identification, assessment, and therapy of small cell lung cancer
SE0202483D0 (sv) 2002-08-21 2002-08-21 Astrazeneca Ab Chemical compounds
ES2403932T3 (es) 2002-08-27 2013-05-22 Biokine Therapeutics Ltd. Antagonista de CXCR4 y uso del mismo
DE10240064A1 (de) 2002-08-30 2004-03-11 Universitätsklinikum Freiburg CXCR4-Rezeptor-Antagonisten
EP1550657A4 (en) * 2002-09-11 2009-12-30 Kureha Corp AMINO COMPOUNDS AND THEIR USE
JP4391123B2 (ja) 2002-10-24 2009-12-24 株式会社オーファンリンク 新規cxcr4アンタゴニスト
JP2006511500A (ja) * 2002-10-30 2006-04-06 メルク エンド カムパニー インコーポレーテッド γ−アミノアミド系のケモカイン受容体活性調節剤
US20040132642A1 (en) 2002-11-12 2004-07-08 Government Of The U.S.A., Represented By The Secretary, Dept. Of Health & Human Services Methods of inhibiting metastasis or growth of a tumor cell
EP1571146A4 (en) 2002-12-10 2010-09-01 Ono Pharmaceutical Co NITROGENIC HETEROCYCLIC COMPOUNDS AND THEIR MEDICAL USE
WO2004054603A2 (en) 2002-12-13 2004-07-01 Case Western Reserve University Use of beta-defensins for treating hiv infections
US20050002939A1 (en) 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
EP1615633B1 (en) 2003-04-22 2012-08-15 Genzyme Corporation Chemokine receptor binding heterocyclic compounds with enhanced efficacy
ES2306924T3 (es) 2003-05-02 2008-11-16 Polyphor Ag Peptidomimeticos fijados a una matriz como medicamentos contra el vih y el cancer.
AU2003232253A1 (en) 2003-05-02 2004-11-23 Polyphor Ag Template-fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity
JP2004359689A (ja) 2003-06-05 2004-12-24 Abbott Gmbh & Co Kg ドーパミンd3受容体のモジュレーションに反応する障害の治療に適するトリアゾール化合物
WO2005002522A2 (en) 2003-06-30 2005-01-13 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Compositions and methods for treating tissue ischemia
EP1493438A1 (en) 2003-07-03 2005-01-05 Bayer HealthCare AG Vanilloid receptor (VR) inhibitors for treatment of Human Immunodeficiency Virus (HIV)-mediated pain states
ITMI20031754A1 (it) 2003-09-12 2005-03-13 Fabrizio Marcucci Composizione microbicida.
US20050192272A1 (en) 2003-12-22 2005-09-01 Garland Marshall Substituted benzodiazepines as inhibitors of the chemokine receptor CXCR4
GB0404434D0 (en) 2004-02-27 2004-03-31 Novartis Ag Organic compounds
CA2558600C (en) * 2004-03-10 2013-07-09 Kureha Corporation A substituted-trialkyl amine compound with anti-viral activity based on antagonism against a chemokine receptor cxcr4
US20050215544A1 (en) 2004-03-24 2005-09-29 Pin-Fang Lin Methods of treating HIV infection
US20050215543A1 (en) 2004-03-24 2005-09-29 Pin-Fang Lin Methods of treating HIV infection
US7776863B2 (en) 2004-03-24 2010-08-17 Bristol-Myers Squibb Company Methods of treating HIV infection
WO2006020415A1 (en) 2004-08-02 2006-02-23 Smithkline Beecham Corporation Chemical compounds
CA2577100A1 (en) 2004-08-16 2006-03-02 Smithkline Beecham Corporation Chemical compounds
EP1790639B1 (en) * 2004-08-27 2014-03-26 Ono Pharmaceutical Co., Ltd. Spirocyclic compounds and their use as cxcr4-antagonists
US20080096859A1 (en) 2004-10-01 2008-04-24 Sullivan Kathleen A Compositions and Methods for Treating Ophthalmic Diseases
US20060265312A1 (en) 2005-03-18 2006-11-23 Spencer Rascoff Online real estate auctions

Also Published As

Publication number Publication date
EP1942108A1 (en) 2008-07-09
ES2427989T3 (es) 2013-11-05
WO2007049771A1 (ja) 2007-05-03
US8871210B2 (en) 2014-10-28
EP2657235A1 (en) 2013-10-30
US20120328627A1 (en) 2012-12-27
EP1942108A4 (en) 2010-10-20
EP1942108B1 (en) 2013-09-04
JP2013032397A (ja) 2013-02-14
US20090118279A1 (en) 2009-05-07
US20140072576A1 (en) 2014-03-13
PT1942108E (pt) 2013-10-24
US8318931B2 (en) 2012-11-27
DK1942108T3 (da) 2013-12-09
JP5251127B2 (ja) 2013-07-31
US8614323B2 (en) 2013-12-24
JPWO2007049771A1 (ja) 2009-04-30

Similar Documents

Publication Publication Date Title
EP1790639A4 (en) A BASIC GROUP CONNECTING AND APPLYING THEREOF
EP1942108A4 (en) BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF
GB0512940D0 (en) Compounds and their use
IL185223A0 (en) Compounds and uses thereof
GB0520743D0 (en) Compounds and their use
SI2497780T1 (sl) Spojine, povezane s TDF, in njihovi analogi
IL192820A0 (en) Novel compounds and use thereof
GB0804899D0 (en) Compound composition and use
ZA200804378B (en) Iminopropene compound and use thereof
GB0427723D0 (en) Compounds and their use
GB0521278D0 (en) Compounds and their use
GB0513176D0 (en) Compounds and their use
GB0521272D0 (en) Compounds and uses thereof
GB0514416D0 (en) Compounds and uses thereof
GB0410114D0 (en) Compounds and their use
GB0403953D0 (en) Compounds and their use
GB0409379D0 (en) Compounds and their use
GB0409377D0 (en) Compounds and their use
GB0410830D0 (en) Compounds and their use
GB0410831D0 (en) Compounds and their use
GB0410832D0 (en) Compounds and their use
GB0410833D0 (en) Compounds and their use
GB0411071D0 (en) Compounds and their use
GB0416630D0 (en) Compounds and their use
GB0423234D0 (en) Compounds and their use